• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1,1-Dioxides of penicillanic acid and esters are described which are useful as beta -lactamase inhibitors. These compounds are 1,1-dioxides of penicillanic acid and of corresponding esters which are easily hydrolysable in vivo, derivatives of penicillanic acid 1,1-dioxide, the carboxyl radical of which is protected by a standard protective group of the carboxyl radical of penicillins, which are useful intermediates for the synthesis of penicillanic acid 1,1-dioxide, and 1-oxides of penicillanic acid and of certain of its esters which are useful as chemical intermediates for the synthesis of penicillanic acid 1,1-dioxide and of its esters. These 1,1-dioxides of penicillanic acid and esters are antibacterial agents, also capable of increasing the effectiveness of various antibiotics of the beta -lactam type with respect to bacteria which produce beta -lactamase.
    公开号:SU860706A1
    申请号:SU782624408
    申请日:1978-06-06
    公开日:1981-08-30
    发明作者:Эрнст Барт Вэйн
    申请人:Пфайзер Инк (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new antibiotics of the penicillin series, namely penicillic acid 1,1-dioxides or its esters of the formula
    ABOUT /
    N. -Y
    . SNS SNS,
    -to
    COOR
    about
    where R is a hydrogen atom, 3-phthalidyl, (lower) alkanoyloxymethyl, 1- (lower) alkanoyloxyethyl, 1-methyl-1- (lower) alkanoyloxyethyl or 1- (lower) alkoxycarbonyloxyethyl, or in the case when R is a hydrogen atom, their salts, which can be used as antibacterial agents.
    A known method for the preparation of S-oxide of 6-amino- or 6-acylamino-penicillanic acid by the interaction of the corresponding 6-amino or 6-acylamino-penicillanoic acid with an oxidizing agent, in particular an organic or inorganic peracid or its metal salt G1.1
    However, these compounds exhibit antibacterial activity.
    The purpose of the invention is to obtain new compounds expanding the arsenal of means of influencing a living organism.
    This goal is achieved by a penidillin-based S-oxidation reaction, which is
    10 what is the compound of formula
    Sh
    15
    or
    N. S .. СНз
    G Y-.CHj
    w
    --N-- ..
    COOR
    g
    25
    where R has the meanings given for R or is the carboxyl protecting group in penicillanic acid. group, for example, benyl, 4-nitrobenzyl or 2,2,2-trichlor30
    ethyl, exposed to an oxidizing agent in an inert solvent and a temperature of -20-5СГС, and the target product is isolated when R has the values indicated for R or, if necessary, removes the carboxyl protecting group, and / or translates, if desired the target product, when R is a hydrogen atom, by reacting with a base in its salt.
    For oxidation, various known oxidizing agents used for the oxidation of sulfoxides to sulfones can be used. But especially convenient oxidizing agents are metal permanganates, such as alkali metal permanganates, and peroxide organic acids, such as organic percarboxylic acids. Examples of such reagents are sodium permanganate, potassium permanganate 3-chloroperbenzoic acid and peracetic acid ..
    If a compound of formula I or I1I is oxidized to the corresponding compound of formula I with a metal permanganate, the reaction is usually carried out by the reaction of a compound of formula
    II or II t with 0.5-5 mol-eq of permanganates, preferably with 1 mol-eq of permanganate in an appropriate solvent. Such a solvent is a solvent that does not react.
    neither with the original substance nor with the reaction product. Water is usually used. If desired, additional solvent may be added which is miscible with water but does not react with a permanganate, for example tetrahydrofuran. The reaction is usually carried out at a temperature of from -20 ° C to better at. At temperatures around the reaction, the reaction is usually complete in a short time, for example, for 1 hour. Although the reaction can be carried out in a neutral, acidic or basic environment, it is better to conduct it in an almost neutral environment to avoid decomposition of the j5-lactam ring of the compound of formula I. Buffer the pH of the reaction medium near neutral. The product is isolated by conventional means. An excess of permanganate is usually decomposed with sodium bisulfite and, if the product falls out of solution, it is isolated by filtration. It is separated from manganese dioxide by extraction with an organic solvent, followed by distilling off the solvent. If the product does not fall out of solution. At the end of the reaction, it is extracted by solvent extraction.
    If the compound of formula II or
    III is acidified to the corresponding compound of formula I with an organic peracid, for example, underoxycarboxylic acid, the reaction is usually carried out by treating the compound of formula II or
    i1t 1-4 mol eq, preferably about 1.2 ec of oxidant in an inert organic solvent. Such solvents are chlorinated hydrocarbons, for example, dichloromethane, chloroform or 1,2-dichloroethane, ethers, for example, diethyl ether, tetrahydrofuran or 1,2-dimethoxyethane. The reaction is usually carried out at a temperature from, to, preferably at a temperature of about. At a temperature of 25 ° C, the reaction time is usually from 2 to 16 hours. The product is usually isolated by distilling off the solvent in vacuo. The product can be cleaned by known methods.
    When the compound is oxidized (I or
    II. It is sometimes advantageous to add a catalyst, for example, a manganese salt (manganous acetylacetate) to the compound of formula I with the aid of an organic peracid.
    When a compound of formula IV is used as a starting material, the process is carried out under the same conditions as in the case of the oxidation of compounds
    II or III, but usually double the amount of oxidant 110 molJ; eq of alkali metal permanganate or 2-8 molar equivalents of organic peracid (acetylacetonate}.
    A compound of the formula I, where R is a hydrogen atom, can also be obtained by removing the protective group R from a compound of the formula t, where R is the carboxy protecting group of penicillin. R may be any carboxy-protecting group commonly used in penicillin chemistry to protect the carboxy group in the 3rd position.
    The carboxy protective group I must be stable during the oxidation of compound H, III or IV, it must be removed from the compound of formula I under conditions in which β-lactam remains almost intact. Salts of the compounds of formula 1 can be obtained by standard methods, for example by displacing acidic and basic components, usually in a 1: 1 ratio in an aqueous, non-aqueous or partially aqueous medium. The salts are then isolated by filtration, precipitation with a solvent, in which the salt does not dissolve, followed by filtration, evaporation of the solvent or, in the case of an aqueous solution, by lyophilization. Organic or inorganic bases can be used for salt formation, examples of which are ammonia, organic amines, alkali metal hydroxides, their carbonates, bicarbonates, hydrides or alcohols, alkali hydrogeihydroxides, their carbonates, hydrides or alcohols. Examples of such bases are primary amines, for example, propylamine, butylamine, aniline.
    cyclohexylamine, benzylamine, or octylamine, secondary amines, for example, diethylamine, morpholine, pyrrolidine or piperidine, tertiary amines, for example, triethylamine, N-ethylpiperidine, N-methylmorpholine or 1,5-diazobicyclo (4,3,0) -non- 5-ene, hydroxides, e.g. sodium, ammonium or barium hydroxide, alcohols, e.g. sodium ethoxide or potassium ethylate, hydrides, e.g. calcium hydride or sodium carbonates, e.g. potassium or sodium carbonate, bicarbonates e.g. sodium or potassium bicarbonate , alkali metal salts and long chain fatty acids, for example, 2-ethylg exanoate sodium.
    Preferred salts of the compounds of formula I are sodium, potassium or triethylamine salts.
    The compounds of the formula I or its salts are active antibacterial agents m vivo. To determine this activity in mice, an acute experimental infection is created by intraperitoneally inoculating a standard culture of the test microorganism suspended in 5% porcine mucin. The severity of the infection is standardized in such a way that mice receive from 1 to 10 times the dose L of the microorganism (L is the minimum inoculation of the microorganism that requires 100% of the infected, not receiving any treatment of the control mice to completely kill the infected mice. The test compound is administered to the infected mice in fractional doses. At the end of the experiment, the activity of the compound is determined by counting the number of surviving animals from the treated drugs and expressing the activity of the compound in percent of the surviving animals.
    The in vivo antibacterial action of compounds of the formula I, where R is a hydrogen atom, makes them useful as an industrial antimicrobial agent, for example, in water treatment, in combating sludge, preserving color and wood, and also for external EO use as a disinfectant. When the compound is used as an external agent, the active ingredient is often mixed with a non-toxic carrier, for example, vegetable or mineral oil or emollient cream. It may also be dissolved or dispersed in liquid diluents or solvents, for example, water, alcohols, glycols, or mixtures thereof. In most cases, it is convenient to use the concentration of the active ingredient O, 1 to 10% by weight of the total composition.
    The in vivo activity of compounds of the formula I or their salts makes them useful for combating bacterial
    infections in mammals, including humans, in both oral and parenteral routes of administration. These compounds can be used to combat infections caused by susceptible bacteria in humans, for example, infections caused by a strain of Nefsseria gonorrhoeae.
    When considering the use of a crib, the compounds of formula I or its salt for mammals, especially
    10 people, this compound can be administered alone or in a mixture with pharmaceutically acceptable carriers or diluents. They can be administered orally or parenterally, for example, intramuscularly, subcutaneously or intraperitoneally. The carrier or diluent is selected depending on the method of administration. A pharmaceutical composition containing a counter bacterial agent of the formula I may contain from 20 to 95% of the active ingredient.
    For the treatment of people against susceptible microorganisms, a dose is established which depends on the age, weight and response of the individual patient, as well as on the nature and severity of the patient's symptoms. The compounds of the invention are typically administered orally in doses of from 10 to 200 mg / kg.
    30 body weight per day, parenterally from 10 to 400 mg / kg of body weight per day. In cases where these doses may be outside the specified limits.
    In addition, compounds of formula I
    5 or their salts are potent inhibitors of microbial | b-lactamase, they increase the antibacterial effect of p-lactam antibiotics (penicillins and cephalosporins). Against many microorganisms, especially against those producing p-lactamase. The amount at which the compounds of formula I increase the effect of the J5 lactam antibiotic can be established empirically.
    five
    When using penicillanic acid 1,1-dioxide or its ester, which is easily hydrolyzed in vivo in combination with another ft-lactam antibiotic, the sulfone can be injected
    0 or parenterally, for example, intramuscularly, subcutaneously, or intraperitoneally. The ratio of the daily dose of 1,1-dioxide penicillanic acid or its ester or salt and P-lactam-.
    The 5th antibiotic is usually between 1: 3 and 3: 1.
    The daily oral dose of each component of oily amounts to from 10 to 200 mg / kg body weight, while
    The parenteral dose of each component is usually from 10 to 400 mg / kg body weight. In some cases it is necessary to apply doses outside the specified limits.
    5, the IR spectrum is determined on KB g plates or in a solution solution in a nujole; the absorption bands are given in wavelengths (). The NMR spectrum is determined at 60 Hz for a solution in deuterochloroform {CDC C), perduter dimethylsulfoxy de (OM-SO-d) or deuterium oxide (DjO), peak positions are expressed in parts (ppm) with respect to tetramethylsilane or 2,2-Dimethyl-2-silapentan-5-sodium sulfonate. The following abbreviations are used for the shape of the peaks: S - singlet, d doublet, t - triplet, q - quartet, m - multiplet. Example 1. Penicillanic acid 1,1-dioxide. To a solution of 6.51 g (41 mol) of potassium permanganate in 130 ml of water and 4.95 ml of glacial acetic acid, cooled before, is added a 6 ml (about 5 ° C) solution of 4.58 g (21 mmol) of sodium salt penicillic acid in 50 ml of water. The mixture was stirred at about 5 ° C for 20 minutes, then the cooling bath was removed. Solid sodium bispot is added until the potassium permanganate color disappears, then the mixture is filtered. To the aqueous filtrate is added half its volume with a saturated solution of sodium chloride, then the pH of the medium is adjusted to 1.7. The acidic solution is extracted with ethyl acetate. The extracts are dried and evaporated in vacuo. Get 3.47 finished product. The aqueous mother liquor is saturated with sodium chloride and further extracted with ethyl acetate. The ethyl acetate solution is dried, evaporated in vacuo, and another 0.28 product is obtained. Total yield 3.75 g (yield 78%). The NMR spectrum (OM-SO-d) of the product shows absorption at 1.40 (S, ZN), 1.50 (S, ZN), 3.13 (d 1H, C 16 Hz, li 2 Hz), 3, 63 (d ,, 1H, C 16 Hz, Hz), 4.22 (S ,, 1H) and 5.03 (d ,. 1H, K, 4 Hz, I ,, -.2 Hz / h / million .). Example 2. 1,1-dioxide benzylpenicillanate. To a stirred solution of 6.85 (24 mmol) benzylpenicillanate in 75 ml of chloroform purified from ethanol under a nitrogen atmosphere with ice cooling are added in two portions several times over 4.78 g with an 85% frequency of 3-chloroperbenzoic acid. 30 minutes in the left bath, then 45 minutes without external cooling. The reaction mixture is washed with aqueous alkali (pH 8.5 with a saturated solution of sodium chloride, then dried, evaporated in vacuo to give 7.05 g of residue. An examination of this residue shows that it is a mixture of 1-oxide: and benzylpenicillanate and 1, 1-dioxide benelylpeninyllanate (5.5: 1). To a stirred solution of this mixture of 4.85 i sulfoxide-sulfone (5.5: 1) in 50 ml, not containing ego ({ol chloroform, under nitrogen atmosphere is added at room temperature the temperature of 3.2 g of 86% 3-chloroperbenzoic acid. The reaction mixture is stirred for 2.5 h, then it was diluted ethyl acetate. The resulting mixture is added to water at a pH of 8.0, then the layers are separated. The organic phase is washed with water at a pH of 8.0, then with a saturated solution of sodium chloride, then dried by sodium sulfate. After evaporation in vacuum, 3.59 g are obtained the finished compound. The NMR spectrum of the product (in CDCI-3) shows the absorption at 1.28 (S, 3N), 1.58 (S, .H), 3.42 (t, 2H), 4.3 (S, 1H), 4.55 (w, 1H), 5.18 (q, 2H 1 12 Hz) and 7.35 (S, 5H) ppm. Example 3. Penicillanic acid 1,1-dioxide. To a stirred solution of 8.27 g of benzylpenicillanate 1,1-dioxide in a mixture of 40 ml of methanol and 10 ml of ethyl acetate are slowly added 10 ml of water, then 12 g of 50% palladium on calcium carbonate. The mixture was shaken under a hydrogen atmosphere at 3.7 atm for 40 minutes, then filtered through diatomaceous earth. The filter cake was washed with methanol and aqueous methanol, and the washes were added to the filtrate. This solution is evaporated in vacuo to remove most of the organic solvents, then the residue is partitioned between ethyl acetate and water at a pH of 2.8. The ethyl acetate layer is removed and the aqueous stem is extracted once more with ethyl acetate. The combined ethyl acetate extracts are washed with a saturated solution of sodium chloride, dried with sodium sulfate and evaporated in vacuo. The residue is suspended in a mixture of ethyl acetate-ether and receive 2.37 g of the final product with so pl. 148-51 C. The mixture of ethyl acetate-ether is evaporated and another 2.17 g of product is obtained, Example 4, pivaloyloxymethyl penicillanate 1,1-dioxide. To 0.615 g (2.41 mmol) of 1,1-dioxide penicillanic acid in 2 ml of N, N-dimethylformamide were added 0.215 g (2.5 mmol) of diisopropylethylamine, then 0.365 g of chloromethyl pivalate. The reaction mixture is stirred at room temperature for 24 hours, then it is diluted with ethyl acetate and water. The ethyl acetate layer is separated and washed three times with water and once with a saturated solution of sodium chloride. The cyruai ethyl acetate solution, anhydrous sodium sulfate, is evaporated to obtain 0.700 g of the finished product as a solid.
    with: i-.uu. lOl-I C. NMR-ciiniiIp llpcviyK-i, i ü (G. OSC) absorbs absorption at, 27 (S, 9H), 1., 47 (S, ZN), 1.62 (S, ZN), 3 , 52 (t, 211), 4.47 {S, 1H), 4.70 (t, 1H), G, 73 {d, 1H, I 6 Hz) and 5.98 (d, 1H, (6, 0 Hz
    Example 5. 1,1-dioxide 3-phthalylphenicillanate,
    To 0.783 g (3.36 mmol) of penicillanic acid 1,1-dioxide in 5 m N, N-dimethylformamide, 0.47 ml of triethylamine was added, followed by 0.715 g of 3-bromophthalide. The reaction mixture is stirred at room temperature for 2 hours, then diluted with ethyl acetate and water. The pH of the aqueous phase is increased to 7.0 g and the layers are separated. The ethyl acetate layer was washed successively with water and a saturated solution of sodium chloride, then it was dried with sodium sulfate. The ethyl acetate solution is evaporated in vacuo and the finished product is obtained as a white foam. The NMR spectrum of this product in (CDClI shows the absorption at 1.47 (S, 6H), 3.43 (t, 1H), 4.45 (S, 1H), 4.62 (t, 1H), 7.40 and 7.47 (2S, 1H) 7.73 (t, 4H) h / min.
    Example 6. 1,1-dioxide 1- (ethoxycarbonyloxy) -ethylpenicillanate.
    A mixture of 0.654 g of penicillanic acid 1,1-dBuoxide, 0.42 ml of triethylamine, 0.412 g of 1-chloroethylethyl carbonate, 0.300 g of sodium bromoane and 3 ml of N, N-dimethylformamide is stirred at room temperature for 6 days. The mixture is diluted with ethyl acetate and water, then the pH is adjusted to 8.5. The ethyl acetate layer is separated three times, washed with water, once washed with a saturated solution of sodium chloride, then dried with anhydrous sodium sulfate. The ethyl acetate was distilled off in vacuo to give 0.390 g of the final product as an oil. This product is combined with an approximately equal amount of the same substance from a similar experiment. The combined products were dissolved in chloroform and 1 ml of pyridine was added. The mixture was stirred at room temperature overnight, then stirred at room temperature overnight, after which chloroform was distilled off in vacuo. The residue is partitioned between ethyl acetate and water at pH 8.0. Then, the separated and dried ethyl acetate is evaporated at vacuum B to obtain 150 mg of the finished product (yield about 7%). The IR spectrum (film) of this product shows absorption at 1805 and 1763 cm, NMR spectrum (CDClj) shows absorption at 1.43 (t, 12H), 3.47 (t, 2H), 3.9 (q, 2H, , I 7.5 Hz), 4.37 (in, 1H), 4.63 (t, 1H) and 6.77
    (m, П1) Ch. / MLN.
    Example 7. 1, .1-d penicillanic acid oxide.
    To 2.17 g (10 mmol) 1a (g-oxide of the penicillan acid in 30 ml of chloroform purified from ethanol, 1.73 g (10 mmol) of 3-chloroperbenzoic acid are added at a temperature of about. Then the mixture is stirred for 1 h. h at. The filtered reaction mixture is evaporated JQ in vacuo and receive penicillanic acid 1,1-dioxide.
    Example 8. Penicillanic acid 1,1-dioxide.
    Hydrogenolysis of 1,1-dioxide 4-nitrobenzyl penicillanate, similarly to measure 3, gives 1,1-dioxide penicillanic acid.
    Example 9. Sodium penicillanate 1,1-dioxide.
    A solution of 25.7 g (0.155 mol) of sodium 2-ethylhexanoate in 200 ml of ethyl acetate was added to a stirred solution of 20 32.75 g (0.14 mol) of 1,1-dioxide penicillanic acid in 450 ml of ethyl acetate. The resulting 25 solution is stirred for 1 hour, then an excess of 10% sodium 2-ethylhexanoate is added in a small volume of ethyl acetate. The product immediately begins to precipitate, stirring is continued Q for 30 minutes and the precipitate is filtered. Sediment
    washed with ethyl acetate, then with a mixture of ethyl acetate-ether (1: 1) and ether. Then the precipitate is dried with phosphorus pentoxide at a vacuum of 0.1 mm Hg. for - 16 hours, 36.8 g of the final compound, contaminated with a small amount of ethyl acetate, is obtained, which is removed by heating for 3 hours under vacuum. The IR spectrum of this final product (KBN disks) shows absorption at 1768 and 1608. cm, NMR spectrum (05.0) shows absorption at 1.48 (S, 3N), 1.62 (S, 3N), 3.35 (d, 1H, L 16 Hz, IJ. 2 Hz), 3.70 (d, 1H, 5 I. 16 Hz, I 4 Hz), 4.25 (S, 1H), 03 (d, 1H, 1 4 Hz, I 2. 2 Hz) ppm The sodium salt can be obtained using acetone instead of ethyl acetate.
    0 Example 10. Penicillanic acid 1,1-dioxide.
    权利要求:
    Claims (6)
    [1]
    To a mixture of 7600 ml of water and 289 ml of glacial acetic acid, 379.5 g of potassium permanganate are added in portions. The mixture is stirred for 15 min, then cooled to 0 ° C. Then, while stirring, a mixture of 270 g of penicillanic acid, 260 ml (4 g) of sodium hydroxide and 2400 ml of water (pH 7.2) is added, then cooled to 8 ° C. When the mixture is added, the temperature rises to. The temperature of the mixture obtained is reduced to 5 ° C and mixed for 30 minutes. Then, to the reaction mixture, 142.1 g of isulfate sulfate was added in 5 portions over 10 minutes. The mixture was stirred for 10 minutes at, then 100 g of diatomaceous earth was added. Stir for another 5 minutes and filter. To the filtrate was added 4.0 L of ethyl acetate, then the pH of the aqueous layer was lowered to 1.55 with 6N. hydrochloric acid. The ethyl acetate laminate is combined with several further ethyl acetate extracts. The combined organic layers are washed with water, dried with sodium sulfate and evaporated in vacuo. The resulting suspension is stirred with 700 ml of ether for 20 minutes, then filtered. 82, .6 g are obtained in the precipitate (yield 26% of the 5 final compound with mp 154-155, (decomposition). Example 11. 1,1-Dioxide of paloyloxymethyl penicillanate. To a solution of 1.25 g of pivaloyloxymethyl penicillanate in 40 ml of chloroform, cooled to a temperature of about -15 ° C, is added 0.8 g of 3-chloroperbenzoic acid. The mixture is stirred for 20 minutes and then allowed to warm to room temperature. Analysis of the resulting NMR solution shows that it contains ioL- and lp-oxide. The chloroform solution is evaporated to a temperature of about 20 ml and another 0.8 g of 3-chloroperbenzoate is added acid. The mixture is stirred at room temperature overnight, then all of the solvent is distilled off in vacuo. The residue is dissolved in (about) 4 ml of dichloromethane and 0.4 g of 3-chloroperbenzoic acid is added. The mixture is stirred for 3 h, then the solvent is distilled off in vacuo.The residue is partitioned between ethyl acetate and water at pH 6.0 and sodium bisulfite is added until the reaction to the presence of peroxides is negative. The pH of the aqueous phase is raised to 8.0 and the layers are separated. The organic layer was washed with brine, dried with anhydrous sodium sulfate, and evaporated in vacuo. The residue is dissolved in ether and precipitated by the addition of hexane. It is then recrystallized from ether to give 0.357 g of the title compound. NMR (COCI) shows absorption at 1.23 (S, 9H), 1.50 (S, 3N), 1.67 (S, 3N), 3.28 (t, 2H), 4.45 ( S, 1H), 5.25 (t, 1H) and 5.78 (t, 2H). Example 12. 1,1-dioxide 3-phthalidylpenicillanate. To a solution of 713 ml of 3-phalidylpene-cyclanate in 3 ml of chloroform, 0.430 g of 3-chloroperbenzoic acid is added at a temperature of about. The mixture was mixed for 30 minutes, then another 0.513 g of 3-chloroanterboisanoic acid was added. The mixture was stirred at room temperature for 4 hours; then the solvent was distilled off in vacuo. The residue is partitioned between ethyl acetate and one at pH = - O, and sodium bisulphite is added to decompose the remaining acid. The pH of the aqueous phase is increased to 8.8, the layers are separated and the organic phase is evaporated in vacuums, the final compound is obtained as a foam. The NMR spectrum (CDCl3) shows absorption at 1.62 (t, 6H), 3.3 (t, 2H), 4.52 (q, 1H), 5.23 (t, 1H) and 7.63 (t , 5H) ppm Example 13. 1,1-dioxide 2,2,2-trichloroethylpenicillanate. 50 mg of 3-chloroperbenzoic acid and a mixture of stirring for 30 minutes are added to a small volume of chloroform to 100 mg of 2,2,2-trichloroethylpenicillanate. Examination of the reaction product shows that it is mostly sulfoxide. NMR spectrum (CDCl1) shows absorption at 1.6 (S, ZN), 1.77 (S, ZN), 3.38 (t, 2H), 4.65 (S, 1H), 4.85 (t , 2H) and 5.7 (t, 1H) ppm. An additional 100 mg of 3-chloroperbenzoic acid is added and the mixture is stirred overnight. The solvent is then distilled off in vacuo and the residue is distributed between ethyl acetate and water at a pH of 6.0. Sufficient sodium bisulfite is added to decompose excess peracid and pH is raised to 8.5. The organic phase is separated, washed with brine and dried .-. After distilling off the solvent, one gets 65 mg of the finished product. NMR spectrum (COClj) shows absorption at 1.53 (S, 3N), 1.72 (S, 2H), 3.47 (t, 2H), 4.5 (S, 1H), 4.6 (t , 1H) and 4.8 (t, 2H) ppm. Example 14. 1,1-dioxide 4-nitrobenzylpenicillanate. A solution of 4-nitrobenzylglyurate of nicillanate in chloroform is cooled to iT and 1 eq of 3-chloroperbenzoic acid is added. The reaction mixture is stirred for 20 minutes. The study of the reaction mixture by the NMR spectrum shows that it contains 1-oxide of 4-n 1trobenzylpenicillanate. An additional 1 eq of 3-chloroperbenzoic acid is added and the reaction mixture is stirred for 4 hours. Another 1 eq of 3-chloroperbenzoic acid is then added and the reaction mixture is stirred overnight. The solvent is distilled off and the residue is partitioned between ethyl acetate and water at pH 8.5. The ethyl acetate layer is separated, washed with water, dried, evaporated to give a crude product. This crude product is purified by chromatography on silica gel, eluted with a mixture (1: 4) of ethyl acetate and chloroform. The NMR spectrum of the product (CDCIj) shows absorption at 1.35 (S, 3N), 1.58 (S, 3N), 3.45 (t, 2H), 4.42 (S, 1H), 4.58 ( t, 1H), 5.30 (S, 2H) and 7.83 (q, 4H) ppm. Example 15. 1,1-dioxide penicillanic acid. To 0.54 g of 1,1-dioxide 4-nitrobeneg1; i1-anate in 30 ml of methanol and 10 ml of ethyl acetate were added 0.54 10% palladium on carbon. The mixture is shaken in a hydrogen atmosphere at a pressure of 3.5 atm until the absorption of hydrogen ceases. The reaction mixture was filtered and the solvent was distilled off. The residue is partitioned between ethyl acetate and water at pH 8.5, and the lower aqueous layer is separated. Fresh, this acetate is added and the pH is adjusted to 1.5. The ethyl acetate layer is separated, washed with water and dried, then it is ground in a vacuum. Thus, 0.168 of the final compound is obtained in the form of a crystalline residue. Example 16. 1,1-dioxide of penicillanic acid. A stirred solution of 512 mg of 1,1-dioxide of 4-nitrobenzylpenicyl nata in a mixture of 5 ml of acetonitrile and 5 ml of water was cooled down and a solution of 484 mg of sodium dithionite in 1.4 tvui 1 N was added in a few minutes sodium hydroxide solution. The reaction mixture was stirred for another 5 minutes and diluted with ethyl acetate and water at pH 8.5. The ethyl acetate layer was separated, evaporated in vacuo to give 300 mg of the desired substance. Fresh ethyl acetate is added to the aqueous phase and the pH is adjusted to 1.5. The ethyl acetate is dried in vacuo to give 50 mg of the complete compound. Example 17. 1,1-Dioxide of 1-methyl-1- (acetoxy) ethylpenicillanate. 1.9 ml of ethyldiis of propylamine are added to 2.33 g of 1,1-dioxide penicillanic acid in 5 ml of M, H-dimethylformamide, then 1.37 g of 1-methyl-1- (acetoxy) ethyl chloride is added dropwise at 20 ° C. The mixture was stirred at room temperature overnight, then the mixture was diluted with ethyl acetate and water. The layers are separated. The ethyl acetate layer is washed with water at pH 9. The ethyl acetate solution is then dried with sodium sulfate, evaporated in vacuo and 1.63 g of crude product is obtained as an oil. The oil hardens on standing in a refrigerator, then it is recrystallized from chloroform and ether and get a substance with so pl. 90-92 The NMR spectrum of the crude product (SOSTS shows absorption at 1.5 (S, 3N), 1.62 (S, 3N), 1.85 (S, 3N), 1.93 (S, 3N), 2 , 07 (S, ЗН), 3.43 (t, 2H), 4.3 (S, 1H) and 4.57 (t, 1H) ppm. Example 18. 1.1-dioxide of penicillanic acid. 1.46 ml of 40% peracetic acid is added to a stirred solution of 1.78 g of penicillanic acid in water at pH 7.5, and after another 30 minutes another 2.94 ml of hO% peracetic acid is added. Day at room temperature, then diluted with ethyl acetate and water. Sodium bisulfate is added to decompose excess peracid and pH is adjusted. The ethyl acetate layer was separated, dried with sodium sulfate, and evaporated in vacuo. The residue was mixed (3: 4} with penicillanic acid 1,1-dioxide and penicillanic acid 1-oxide. Pivaloyloxymethyl penicillanate 1,1-dioxide. Stirring solution 595 mg 1 -oxyaloxyloxymethyl peneniclanate in 5 ml of ethyl acetate was cooled down and 5 mg of manganese acetylacetonate was added to the obtained dark-brown liquid in a few minutes in small portions of 0.89 40% peracetic acid. After 40 minutes, the cooling bath was removed and the mixture was stirred at room temperature for 3 days. The mixture is diluted with ethyl acetate and water at pH 8.5. The ethyl acetate layer is separated, dried and evaporated in vacuo. This gives 178 mg of a substance which, according to NMR spectroscopy, is a mixture of pivaloyloxymethyl penicillanate 1,1-dioxide and pivaloyloxymethyl penicillanate 1-oxide. This substance is dissolved in ethyl acetate and again oxidized with 0.9 ml of peracetic acid and 5 mg of manganese acetylacetate as described above for 16 hours. The reaction mixture is worked up as described above. 186 mg of pivaloyloxymethylpenicillanate 1,1-dioxide is obtained. The invention claims 1. A method for producing penicillanic acid 1,1-dioxides or its esters of formula lower) alkanoyloxyethyl or 1 (lower) alkoxycarbonyloxyethyl, whether in the case when R is a hydrogen atom, their salts, characterized in that the compound of formula II, II or IV. l coos
    § ... chj
    to---.
    Sooa
    where R has the meanings for R or denotes a group protecting a carboxyl group in penicillanic acid, for example, benzyl, 4-nitrobenzyl or 2,2,2-trichloroethyl, is reacted with an oxidizing agent in an inert solvent and a temperature of -20 - 50 ° C and the target product is isolated when R has the values indicated for R or, if necessary, the carboxyl protecting group is removed and / or the target product is converted, if R is a hydrogen atom, by reacting with a base to its salt.
    [2]
    2. A method according to claim 1, characterized in that an alkali metal permanganate or an organic peracid is used as the oxidizing agent,
    [3]
    3. The method according to claim 1, characterized in that for oxidation
    Compounds of formula (II) or (111) use 0.13-5 mol eq of an alkali metal permanganate,
    [4]
    4 The method according to claim 1, wherein the compound of formula (II) or (f I, i) is used to oxidize 1--4 mol - eq of organic peracid.
    [5]
    5, the process according to claim 1, characterized by the fact that for oxidation
    Compounds of formula (IV) use 1-10 mol eq of alkali metal permanganate "
    [6]
    6. The method according to claim 1, characterized in that for the oxidation of the compound of formula (IV) is used
    5 2-8 mol eq of organic peracid. Priority featured:
    06.06.77 when R is a hydrogen atom, 3-phthalidyl, (lower) alkanoyloxymethyl, 1- (lower) alkanoyloxyethyl,
    0 1 (lower) alkoxycarbonyloxyethyl or salt-forming radical.
    02.21.78 when R is 1-methyl-1- (lower) alkanoyloxyethyl.
    Sources of information taken into account in the examination
    I, Patent of England No. 1453301, class, C 2 C, published. 1976.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU860706A1|1981-08-30|Method of preparing 1,1-dioxides of penicillanic acid or its esters or its salts
    US4234579A|1980-11-18|Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
    SU1122227A3|1984-10-30|Method of obtaining 6beta-oxyalkylpenicillanic acid derivatives or their pharmaceutically suitable basic salts
    US4276285A|1981-06-30|Combinations of penicillanic acid 1,1-dioxide with 7-|-3-|-3-desacetoxymethylcephalosporanic acid
    EP0045198A2|1982-02-03|1,1-Disubstituted carba-2-penems and their production
    CA1150242A|1983-07-19|ACETOXYMETHYL PENAM COMPOUNDS AS .beta.-LACTAMASEINHIBITORS
    US4420426A|1983-12-13|6-Alpha-halopenicillanic acid 1,1-dioxides
    SU1192626A3|1985-11-15|Method of producing 1,1-dioxide of penicillanic acid or ether thereof
    EP0181702B1|1989-05-31|6-substituted penicillanic acid 1,1-dioxide compounds
    DD149366A5|1981-07-08|PROCESS FOR THE PREPARATION OF PENICILLANIC ACID DERIVATIVES
    CS236681B2|1985-05-15|Manufacturing process of 1,1-dioxide ester 2beta-substituted 2alfa-methyl 5r penam-3alfa-carboxyl acid
    US4714761A|1987-12-22|6,6-dihalopenicillanic acid 1,1-dioxides and process
    US4762920A|1988-08-09|6,6-Dihalopenicillanic acid 1,1-dioxides
    KR820000740B1|1982-05-03|Process for preaprign penicillanic acid 1,1-dioxides
    KR810002025B1|1981-12-15|Process for preparing penicillanic acid 1,1-dioxides
    US4613462A|1986-09-23|6-substituted penicillanic acid 1,1-dioxide compounds
    EP0066373A1|1982-12-08|Beta-lactam derivatives, a process for their preparation and compositions containing them
    US4661480A|1987-04-28|Formamido oxacephems
    CA1129773A|1982-08-17|PENICILLANIC ACID 1,1-DIOXIDES AS .beta.-LACTAMASEINHIBITORS
    SU944505A3|1982-07-15|Process for producing esters of 1,1-dioxide of penicillanic acid
    DK156480B|1989-08-28|PENICILLANIC ACID-1 OXIDES USED AS INTERMEDIATES IN THE PREPARATION OF THERAPEUTIC ACTIVE PENICILLANIC ACID-1,1-DIOXIDE DERIVATIVES
    NZ199608A|1984-05-31|Administering penicillanic acid 1,1-dioxides with beta-lactam antibiotics
    HU180921B|1983-05-30|Process for producing pharmaceutical compositions containing beta-lactame antibiotic and 2,2-dimethyl-pename-3-carboxylic acid-1,1-dioxide derivativesderivatives
    NZ199601A|1984-07-06|Coadministration of a cephalosporin derivative and a penicillin
    CS227349B2|1984-04-16|Method of preparing 1,1-dioxopenicillanoyloxymethyl-6-|-penicillanate
    同族专利:
    公开号 | 公开日
    NL930064I2|1994-04-18|
    EG13869A|1983-03-31|
    BG34614A3|1983-10-15|
    SG65383G|1985-03-29|
    IL62168D0|1981-03-31|
    DK251478A|1978-12-08|
    NL7806126A|1978-12-11|
    GR72255B|1983-10-06|
    SE8305916D0|1983-10-27|
    NO152448C|1985-10-02|
    FI781800A|1978-12-08|
    CS208472B2|1981-09-15|
    PL114501B1|1981-02-28|
    DK155740C|1989-10-23|
    NO823126L|1978-12-08|
    IT7824270D0|1978-06-06|
    FR2393805B1|1984-02-24|
    IE781140L|1978-12-07|
    HU180042B|1983-01-28|
    PL207396A1|1979-06-04|
    DD148585A5|1981-06-03|
    NL180009C|1986-12-16|
    SE7806628L|1978-12-08|
    PH26810A|1992-11-05|
    FI66003B|1984-04-30|
    AR224111A1|1981-10-30|
    GB2000138A|1979-01-04|
    NO152448B|1985-06-24|
    PH21116A|1987-07-16|
    ATA411278A|1980-06-15|
    SE436206B|1984-11-19|
    NO151746C|1985-06-05|
    LU79774A1|1980-01-22|
    DK155740B|1989-05-08|
    MY8500092A|1985-12-31|
    FR2393805A1|1979-01-05|
    DE2824535A1|1978-12-14|
    IT1096381B|1985-08-26|
    ATA128580A|1981-02-15|
    IL54867A|1981-11-30|
    OA05964A|1981-06-30|
    DE2857263C3|1981-12-17|
    AT364084B|1981-09-25|
    IN149747B|1982-04-03|
    SE8305916L|1983-10-27|
    DE2857263B2|1981-04-23|
    GB2000138B|1982-03-03|
    AU3683878A|1979-12-06|
    YU117078A|1983-01-21|
    IL54867D0|1978-08-31|
    PH16465A|1983-10-20|
    NO151746B|1985-02-18|
    DE2824535C3|1981-01-22|
    CH634073A5|1983-01-14|
    IE47079B1|1983-12-14|
    FR2393804A1|1979-01-05|
    NL930064I1|1993-09-01|
    AU513636B2|1980-12-11|
    NZ187476A|1982-08-17|
    AT360649B|1981-01-26|
    YU41829B|1988-02-29|
    FR2393804B1|1980-11-07|
    SE447995B|1987-01-12|
    BG34615A3|1983-10-15|
    NO781970L|1978-12-08|
    HK13184A|1984-02-24|
    FI66003C|1984-08-10|
    BE867859A|1978-12-06|
    KE3355A|1983-12-16|
    PT68146A|1978-07-01|
    DD140888A5|1980-04-02|
    DE2824535B2|1980-05-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3197466A|1961-10-30|1965-07-27|Smith Kline French Lab|Penicillin sulfoxides and process|
    LU77306A1|1977-05-09|1979-01-18|
    AU3796278A|1977-07-13|1980-01-17|Glaxo Group Ltd|Penams and azetidinones|LU77306A1|1977-05-09|1979-01-18|
    DE2912511C2|1977-06-07|1982-06-24|Pfizer Inc., 10017 New York, N.Y.|Pharmaceutical composition containing penicillanic acid|
    DK155942C|1977-12-23|1989-10-23|Pfizer|METHOD OF ANALOGUE FOR THE PREPARATION OF 6-AMINOPENICILLANIC ACID-1,1-DIOXIDE AND PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION AND BASIS SALTS.|
    JPS6339570B2|1978-03-24|1988-08-05|Toyama Chemical Co Ltd|
    US4241050A|1978-09-01|1980-12-23|Pfizer Inc.|Penam 1,1-dioxides as beta-lactamase inhibitors|
    CA1158639A|1978-12-11|1983-12-13|William H. Koster|6-bromopenicillanic acid sulfone|
    IE49881B1|1979-02-13|1986-01-08|Leo Pharm Prod Ltd|B-lactam intermediates|
    US4432970A|1979-11-23|1984-02-21|Pfizer Inc.|6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors|
    US4420426A|1979-03-05|1983-12-13|Pfizer Inc.|6-Alpha-halopenicillanic acid 1,1-dioxides|
    US4714761A|1979-03-05|1987-12-22|Pfizer Inc.|6,6-dihalopenicillanic acid 1,1-dioxides and process|
    SE449103B|1979-03-05|1987-04-06|Pfizer|SET TO PENICILLANIC ACID-1,1-DIOXIDE AND ESSERS THEREOF|
    GB2045236A|1979-03-26|1980-10-29|Hoechst Uk Ltd|Oxapenem derivatives|
    US4432903A|1980-09-08|1984-02-21|Pfizer Inc.|Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide|
    US4244951A|1979-05-16|1981-01-13|Pfizer Inc.|Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide|
    US4309347A|1979-05-16|1982-01-05|Pfizer Inc.|Penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide|
    US4488994A|1980-09-08|1984-12-18|Pfizer Inc.|Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide|
    IL59948D0|1979-05-21|1980-06-30|Rech Applications Therap|Penicillanic acid derivatives,their production and pharmaceutical compositions containing them|
    DE3051044C2|1979-06-19|1989-03-30|Leo Pharmaceutical Products Ltd. A/S , Ballerup, Dk|
    US4256733A|1979-09-26|1981-03-17|Pfizer Inc.|Acetoxymethyl penam compounds as β-lactamase inhibitors|
    IL61880A|1980-01-21|1984-11-30|Bristol Myers Co|2beta-chloromethyl-2alpha-methylpenam-3alpha-carboxylic acid sulfone derivatives,their preparation and pharmaceutical compositions containing them|
    US4474698A|1980-12-11|1984-10-02|Pfizer Inc.|Process for preparing esters of penicillanic acid sulfone|
    US4419284A|1981-03-23|1983-12-06|Pfizer Inc.|Preparation of halomethyl estersof penicillanic acid 1,1-dioxide|
    EP0069962B1|1981-07-15|1985-01-02|Kanebo, Ltd.|Novel ester of 1,1-dioxopenicillanic acid, process for production thereof, and use thereof as beta-lactamase inhibitor|
    PT76526B|1982-04-19|1986-01-21|Gist Brocades Nv|Preparation of 6-alpha-bromo- and/or 6,6-dibromopenicillanic acid 1,1-dioxides|
    US4502988A|1983-08-08|1985-03-05|Eli Lilly And Company|Oxidation process|
    EP0139047A1|1983-10-18|1985-05-02|Gist-Brocades N.V.|Process for the preparation of 6,6-dibromopenicillanic acid 1,1-dioxide|
    US4647457A|1983-12-16|1987-03-03|Hoffmann-La Roche Inc.|Penicillanic acid derivatives|
    WO1987006230A1|1986-04-10|1987-10-22|Leo Pharmaceutical Products Ltd. A/S|Method for preparing penicillanic acid derivatives|
    GB8808701D0|1988-04-13|1988-05-18|Erba Carlo Spa|Beta-lactam derivatives|
    CN102977120B|2012-12-14|2015-05-27|江西富祥药业股份有限公司|Method for preparing and crystallizing sulbactam pivoxyl|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US80432077A| true| 1977-06-07|1977-06-07|
    US87938178A| true| 1978-02-21|1978-02-21|LV931230A| LV5516A3|1977-06-07|1993-11-15|Contribution to the penicillan coupling of 1,1-dioxide esters|
    [返回顶部]